JP2017518319A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017518319A5 JP2017518319A5 JP2016571301A JP2016571301A JP2017518319A5 JP 2017518319 A5 JP2017518319 A5 JP 2017518319A5 JP 2016571301 A JP2016571301 A JP 2016571301A JP 2016571301 A JP2016571301 A JP 2016571301A JP 2017518319 A5 JP2017518319 A5 JP 2017518319A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- crystalline form
- pxrd pattern
- solution
- dissolving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 9
- 238000001144 powder X-ray diffraction data Methods 0.000 claims 6
- 239000000155 melt Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229920001477 hydrophilic polymer Polymers 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000007962 solid dispersion Substances 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 229920001531 copovidone Polymers 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021048244A JP2021113192A (ja) | 2014-06-06 | 2021-03-23 | 結晶形 |
| JP2023064709A JP2023089125A (ja) | 2014-06-06 | 2023-04-12 | 結晶形 |
| JP2024179614A JP2025004239A (ja) | 2014-06-06 | 2024-10-15 | 結晶形 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462008786P | 2014-06-06 | 2014-06-06 | |
| US62/008,786 | 2014-06-06 | ||
| PCT/US2015/034371 WO2015188045A1 (en) | 2014-06-06 | 2015-06-05 | Crystal forms |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021048244A Division JP2021113192A (ja) | 2014-06-06 | 2021-03-23 | 結晶形 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017518319A JP2017518319A (ja) | 2017-07-06 |
| JP2017518319A5 true JP2017518319A5 (enExample) | 2018-06-28 |
Family
ID=54767417
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016571301A Pending JP2017518319A (ja) | 2014-06-06 | 2015-06-05 | 結晶形 |
| JP2021048244A Pending JP2021113192A (ja) | 2014-06-06 | 2021-03-23 | 結晶形 |
| JP2023064709A Pending JP2023089125A (ja) | 2014-06-06 | 2023-04-12 | 結晶形 |
| JP2024179614A Pending JP2025004239A (ja) | 2014-06-06 | 2024-10-15 | 結晶形 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021048244A Pending JP2021113192A (ja) | 2014-06-06 | 2021-03-23 | 結晶形 |
| JP2023064709A Pending JP2023089125A (ja) | 2014-06-06 | 2023-04-12 | 結晶形 |
| JP2024179614A Pending JP2025004239A (ja) | 2014-06-06 | 2024-10-15 | 結晶形 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9321807B2 (enExample) |
| EP (2) | EP3151850A4 (enExample) |
| JP (4) | JP2017518319A (enExample) |
| CN (1) | CN106413736A (enExample) |
| AU (2) | AU2015269306B2 (enExample) |
| CA (1) | CA2948902C (enExample) |
| MX (1) | MX373056B (enExample) |
| WO (1) | WO2015188045A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3151850A4 (en) * | 2014-06-06 | 2017-11-29 | AbbVie Inc. | Crystal forms |
| WO2021137256A1 (en) | 2020-01-03 | 2021-07-08 | Mylan Laboratories Limited | Polymorphic forms of glecaprevir |
| GB202113944D0 (en) * | 2021-09-29 | 2021-11-10 | Univ Liverpool | Injectable formulations |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604234A (en) * | 1991-09-05 | 1997-02-18 | Abbott Laboratories | Substituted thiol macrolactam immunomodulators |
| UY28240A1 (es) * | 2003-03-27 | 2004-11-08 | Boehringer Ingelheim Pharma | Fases cristalinas de un potente inhibidor de la hcv |
| KR100995390B1 (ko) * | 2006-01-02 | 2010-11-19 | 주식회사 삼양제넥스 | 무정형, 무수결정형 또는 수화 결정형 도세탁셀의 제조방법 |
| EP2540349B1 (en) * | 2008-07-22 | 2014-02-12 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions comprising a macrocyclic quinoxaline compound which is an hcv ns3 protease inhibitor |
| CN102470158A (zh) * | 2009-08-27 | 2012-05-23 | 默沙东公司 | 制备丙型肝炎病毒的蛋白酶抑制剂的工艺方法 |
| SG188618A1 (en) * | 2010-09-21 | 2013-04-30 | Enanta Pharm Inc | Macrocyclic proline derived hcv serine protease inhibitors |
| MX2014001944A (es) * | 2011-08-19 | 2014-03-27 | Merck Sharp & Dohme | Formas cristalinas de un inhibidor de la proteasa del virus de la hepatitis c. |
| JP6573550B2 (ja) * | 2012-07-12 | 2019-09-11 | アッヴィ・アイルランド・アンリミテッド・カンパニー | Ｈｃｖ阻害剤の結晶形 |
| WO2015061742A2 (en) * | 2013-10-25 | 2015-04-30 | Abbvie, Inc. | Methods for treating hcv |
| EP3151850A4 (en) * | 2014-06-06 | 2017-11-29 | AbbVie Inc. | Crystal forms |
-
2015
- 2015-06-05 EP EP15803592.3A patent/EP3151850A4/en not_active Withdrawn
- 2015-06-05 WO PCT/US2015/034371 patent/WO2015188045A1/en not_active Ceased
- 2015-06-05 CN CN201580029787.7A patent/CN106413736A/zh active Pending
- 2015-06-05 MX MX2016016127A patent/MX373056B/es active IP Right Grant
- 2015-06-05 AU AU2015269306A patent/AU2015269306B2/en active Active
- 2015-06-05 JP JP2016571301A patent/JP2017518319A/ja active Pending
- 2015-06-05 EP EP24151934.7A patent/EP4403223A3/en active Pending
- 2015-06-05 CA CA2948902A patent/CA2948902C/en active Active
- 2015-06-05 US US14/731,765 patent/US9321807B2/en active Active
-
2016
- 2016-04-11 US US15/095,474 patent/US9561181B2/en active Active
-
2020
- 2020-09-23 AU AU2020239679A patent/AU2020239679A1/en not_active Abandoned
-
2021
- 2021-03-23 JP JP2021048244A patent/JP2021113192A/ja active Pending
-
2023
- 2023-04-12 JP JP2023064709A patent/JP2023089125A/ja active Pending
-
2024
- 2024-10-15 JP JP2024179614A patent/JP2025004239A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20241239T1 (hr) | Novi heterociklički derivati korisni kao shp2 inhibitori | |
| IL286912A (en) | Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid | |
| JP2017524067A5 (enExample) | ||
| PH12017501258A1 (en) | Pyrazine compounds for the treatment of infectious diseases | |
| JP2013032389A5 (enExample) | ||
| JP2009523771A5 (enExample) | ||
| JP2011051243A5 (enExample) | ||
| WO2016020320A8 (en) | 2-(morpholin-4-yl)-1,7-naphthyridines | |
| EP3283470A4 (en) | Processes for producing 2,5-furandicarboxylic acid and derivatives thereof and polymers made therefrom | |
| JP2012092123A5 (enExample) | ||
| WO2015142903A3 (en) | Method of controlling lactate production with piperdine-dione derivatives | |
| AR093659A1 (es) | Derivados ciclicos de nucleosidos y usos de los mismos | |
| MX2016008665A (es) | Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo. | |
| EP4327880A3 (en) | Solid state form of ribociclib succinate | |
| WO2014172188A3 (en) | 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors | |
| BR112015023218A2 (pt) | formas sólidas de 5- (halometil)furfural e métodos para preparar as mesmas | |
| JP2017518319A5 (enExample) | ||
| HK1220402A1 (zh) | 新型环孢菌素衍生物和其用途 | |
| JP2017512873A5 (enExample) | ||
| WO2017017039A3 (en) | Plasticized cellulose ester derivatives, a process for its production and its uses | |
| WO2015052568A3 (en) | Solid forms of curcumin and derivatives thereof | |
| WO2010046932A3 (en) | Extended release pharmaceutical composition of minocycline and process thereof | |
| JP2013503145A5 (enExample) | ||
| WO2015002755A3 (en) | Compounds for the treatment of malaria | |
| WO2015128882A3 (en) | Crystalline forms of n-(2,4-di-tert-butyl-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide and process for the preparation thereof |